Clinical Trials Logo

Hepatitis E Infection clinical trials

View clinical trials related to Hepatitis E Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05808166 Not yet recruiting - Clinical trials for Hepatitis E Infection

Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This is a phase II randomized, observer-blinded, placebo-controlled study with 3 arms enrolling a total of 2,358 participants. The arms are composed of Arm 1, pregnant participants receiving Hecolin® (N=1,104) with immunogenicity subset (n=150), Arm 2, pregnant participants receiving placebo (N=1,104) with immunogenicity subset (n=150), and Arm 3, non-pregnant participants receiving Hecolin® (N=150) of which all participants in this arm will be included in the immunogenicity subset.

NCT ID: NCT02759991 Completed - Clinical trials for Hepatitis E Infection

Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.

Start date: October 2, 2017
Phase: Phase 4
Study type: Interventional

The aim of the study is to determine the effectiveness of hepatitis E virus vaccine given in women of child bearing age in preventing HEV disease during pregnancy among women in rural Bangladesh.

NCT ID: NCT01698723 Recruiting - Liver Failure Clinical Trials

A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus

HEVRibavirin
Start date: September 2012
Phase: Phase 2
Study type: Interventional

The term Acute on chronic liver failure (ACLF) describes a clinical entity characterized by an acute and rapid deterioration of liver function in a patient with previously well-compensated liver disease owing to the effects of a precipitating event. In this condition two insults act simultaneously, one being the preexisting liver injury (chronic liver disease) and the other acute injury which is responsible for the acute decompensation. HEV being a major factor responsible for this clinical entity and has a very high mortality rate. Ribavirin being a safe drug and has been shown to inhibit the replication of HEV, can be an important drug in the treatment of these patients. Therefore the present study is designed to study the impact of Ribavirin in reducing the mortality due to HEV related ACLF.